14.01.2020 | Tracker

FDA Tracker: HCPs excited for Keytruda® approval but share reservations about Vascepa®

By Nathan Cripps

FDA Tracker: HCPs excited for Keytruda® approval but share reservations about Vascepa®

CREATION Pinpoint’s Drug Launch Tracker shows how healthcare professionals (HCPs) respond to drug launch news, as it happens. The FDA approved over 339 submissions between 11 December 2019 – 10 January 2020, which included ebola, high risk bladder cancer and to reduce cardiovascular risk.

The most mentioned FDA approvals by HCPs online

Vascepaicosapent ethylAmarin Pharms10078178
KeytrudapembrolizumabMerck & co3101104
LynparzaolaparibAstrazeneca Pharms236184
DayvigolemborexantEisai Inc362258
Enhertufam-trastuzumab deruxtecan-nxkiDaiichi Sankyo301141
Vyondys 53golodirsenSarepta Therapeutics Inc151227
Xeljanztofacitinib citratePfizer23023
AyvakitavapritinibBlueprint Medicines Corp51823
Padcevenfortumab vedotin-ejfvAstellas12820
Fiaspinsulin aspartNovo5914
Caplytalumateperone tosylateIntra-Cellular Therapies Inc10010
Genosylnitric oxideVero Biotech5510
ArazlotazaroteneDow Pharm167
Sertraline Hydrochloridesertraline hydrochlorideMylan404
Duloxetine Hydrochlorideduloxetine hydrochlorideAurobindo Pharma Ltd303
Gilenyafingolimod hydrochlorideNovartis303
PregabalinpregabalinCspc Ouyi303
LamotriginelamotrigineAlembic Pharms Ltd112
Tiglutik KitriluzoleItalfarmaco Spa101
Nouresscysteine hydrochlorideAvadel Legacy101

The most mentioned FDA approval was Vascepa® (icosapent ethyl) with 178 mentions. This product was approved to help reduce the risk of cardiovascular events with a third of the mentions by HCPs likening it to omega-3 or fish oil. One osteopathic physician took this further stating that a non-FDA approved alternative has been around for thousands of years, “It’s called fish”. A tweet by cardiologist Dr. Martha Gulati,  referencing her blog explaining the difference between fish oils, was shared by 17 HCPs.

Keytruda® (pembrolizumab), was approved for the treatment of Bacillus Calmette-Guerin (BCG) – unresponsive high risk patients with bladder cancer. This was the second most mentioned approval by HCPs with 104 mentions. HCPs were predominantly sharing a positive view towards this approval saying that it is ‘fantastic news’ and ‘another landmark for bladder’. The most shared tweet was authored by oncologist Tom Powles, sharing that patients generally want to avoid a cystectomy and with this approval that is now possible.

We are tracking the HCP reaction to FDA approvals and related topics each month. You can keep up to date with this and other pharmaceutical tracking updates within the Tracking section of CREATION Knowledge, or by signing up to our monthly eJournal.


FDA Tracker: Oxbryt and Tecentriq discussed the most by healthcare professionals in November


  • Data for this research was analysed from the online Twitter conversations of HCPs talking about FDA approvals in English language (all other languages are available), between December 11th 2019 and January 10th 2020.
  • Between December 11th 2019 and January 10th 2020, 878 HCPs shared posts about FDA approvals 2,731 times all over the world.
  • The table refers only to approvals that occurred between December 11th 2019 and January 10th 2020. Mentions of approvals before December 11th were not included.
  • HCPs mention brand and compound names when discussing FDA approvals. Approvals may include multiple compounds.

View all articles >

Meet the Author

Nathan Cripps

Suggested next

25.08.2023 | Article

eHCPs in the Netherlands say smoking cessation is more critical than lung cancer screening

What eHCPs in the Netherlands are conversing about online within lung cancer

By Mary Kangley

Transforming your pharma brand strategy: Digital Opinion Leaders

22.01.2020 | Article

Transforming your pharma brand strategy: Digital Opinion Leaders

Transforming your pharma brand strategy: Digital Opinion Leaders

By Luke Wilson

View all articles >